Nevola100 mg

Nevola is a serotonin-norepinephrine reuptake inhibitor (SNRI) antidepressant used mainly to treat depression in adults.

FDA-approved use

• Treatment of Major Depressive Disorder (MDD) in adults.

Uses supported by clinical evidence but not formally FDA-approved (off-label)

• Vasomotor symptoms (hot flashes and night sweats) associated with menopause.
• Adjunctive management of diabetic peripheral neuropathic pain, where evidence is more limited and it is not a first-line choice.

A physician should determine the most appropriate indication and dose for an individual patient; Nevola should not be used for unapproved purposes without medical advice.

Each extended-release tablet contains Desvenlafaxine (as desvenlafaxine succinate) as the active ingredient, commonly available in 50 mg and 100 mg strengths, along with pharmaceutically acceptable excipients.

Nevola is a serotonin-norepinephrine reuptake inhibitor (SNRI) that is the major active metabolite of venlafaxine. It is formulated as an extended-release oral tablet intended for once-daily dosing in the management of major depressive disorder.

Nevola works by increasing the availability of serotonin and norepinephrine in the brain, neurotransmitters believed to play a role in mood regulation.

Nevola belongs to the Serotonin-Norepinephrine Reuptake Inhibitor (SNRI) class of antidepressants.

Desvenlafaxine inhibits the reuptake of serotonin (5-HT) and norepinephrine (NE) in the central nervous system, increasing synaptic concentrations of these neurotransmitters. It has minimal effect on dopamine reuptake and negligible affinity for muscarinic, histaminergic, or adrenergic receptors, which accounts for its comparatively favorable tolerability profile relative to older antidepressant classes.

Desvenlafaxine is well absorbed orally, undergoes hepatic conjugation (not primarily CYP-mediated) and minor CYP3A4-mediated oxidation, and is eliminated mainly via the kidneys, with a plasma half-life of approximately 11 hours supporting once-daily dosing.

Nevola extended-release tablets should be swallowed whole with water, at approximately the same time each day, with or without food. Tablets must not be crushed, chewed, or split, as this may affect the extended-release properties of the medicine. The tablet shell may appear in the stool; this is expected and does not indicate lack of absorption.

Nevola has clinically significant interactions with the following drugs/classes:

• Monoamine oxidase inhibitors (MAOIs): Contraindicated (see Contraindications) due to risk of serious, potentially fatal serotonin syndrome.
• Other serotonergic drugs (SSRIs, other SNRIs, triptans, tramadol, linezolid, intravenous methylene blue, lithium, St. John's Wort): Increased risk of serotonin syndrome when combined with Nevola; combine only with caution and close monitoring.
• CYP3A4 inhibitors (e.g., ketoconazole): May increase Nevola plasma concentrations; dose adjustment or caution may be needed.
• Anticoagulants, antiplatelet agents, and NSAIDs: Concomitant use with Nevola may increase the risk of abnormal bleeding.
• Alcohol and other CNS depressants: May increase sedation or CNS effects when taken with Nevola.

Side effects of Nevola range from common and mild to rare but serious.

Common side effects

• Nausea
• Dizziness
• Insomnia or somnolence
• Excessive sweating (hyperhidrosis)
• Constipation
• Decreased appetite
• Dry mouth
• Anxiety or nervousness
• Sexual dysfunction

Serious side effects (seek medical attention)

• Suicidal thoughts or behavior, especially in children, adolescents, and young adults (see Precautions).
• Serotonin syndrome when combined with other serotonergic drugs.
• Elevated blood pressure.
• Abnormal bleeding or bruising.
• Low sodium levels (hyponatremia), particularly in the elderly.
• Angle-closure glaucoma.
• Activation of mania or hypomania in susceptible patients.

Pregnancy: Nevola should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus, and only under the guidance of a physician. Use of SNRIs, including Nevola, late in the third trimester has been associated with neonatal complications such as respiratory distress, feeding difficulty, and irritability requiring extended hospital monitoring in some cases; a physician should weigh risks of untreated depression against these risks.

Lactation: Nevola is excreted in human breast milk. A decision on breastfeeding should be made with a physician, weighing the benefits of breastfeeding against the possible exposure of the infant to Nevola and the mother's clinical need for treatment.

Boxed Warning

Nevola and other antidepressants carry a boxed warning for increased risk of suicidal thoughts and behavior in children, adolescents, and young adults (up to age 24), especially during the first months of treatment or after dose changes. Patients should be monitored closely for worsening depression or unusual changes in behavior.

Other precautions

• Serotonin syndrome: Risk increases when Nevola is combined with other serotonergic agents (see Interactions); watch for agitation, hallucinations, rapid heart rate, fever, muscle rigidity, and loss of coordination.
• Blood pressure: Nevola can cause sustained increases in blood pressure; blood pressure should be monitored before and periodically during treatment.
• Discontinuation symptoms: Abrupt discontinuation of Nevola can cause dizziness, nausea, headache, irritability, and sensory disturbances; the dose should be tapered gradually under medical supervision.
• Angle-closure glaucoma: Nevola can cause mydriasis (pupil dilation) and may precipitate an attack in patients with untreated anatomically narrow angles.
• Abnormal bleeding: Increased risk, especially when combined with anticoagulants, antiplatelets, or NSAIDs.
• Hyponatremia: More common in elderly patients, those on diuretics, or with volume depletion.
• Activation of mania/hypomania: Use with caution in patients with a history of bipolar disorder.
• Hepatic and renal impairment: Dose adjustment is required (see Dosage and Administration).

Overdose of Nevola may cause symptoms of serotonin syndrome, seizures, rapid heart rate, elevated or lowered blood pressure, drowsiness, or changes in consciousness, particularly when taken with other serotonergic or CNS-active substances.

There is no specific antidote for Nevola overdose. Anyone who has taken more than the prescribed dose, or who shows signs of overdose, should seek immediate medical attention or contact emergency services / a poison control center right away. Treatment is supportive and should be provided in a medical facility.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Renal impairment

Dose reduction of Nevola is required in moderate-to-severe renal impairment and end-stage renal disease (see Dosage and Administration).

Hepatic impairment

No routine adjustment is needed for mild-to-moderate impairment; a reduced maximum dose is recommended in severe hepatic impairment.

Elderly

Elderly patients may be at greater risk of hyponatremia and should be monitored, particularly if also taking diuretics.

Pediatric patients

Nevola is not approved for use in children and adolescents; safety and efficacy have not been established in this population (see Pediatric Uses).

Pregnancy and breastfeeding

See Pregnancy and Lactation section.

An adequate trial of Nevola for depression is generally 4 to 6 weeks before the full antidepressant effect can be assessed. If a response is seen, treatment is usually continued for several months (commonly at least 6 months) as maintenance therapy to reduce the risk of relapse, as advised by the treating physician. Treatment duration should always be individualized, and the medicine should not be stopped abruptly without medical guidance.

Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)

Desvenlafaxine works by selectively inhibiting the reuptake of serotonin and norepinephrine at the neuronal synapse, increasing their concentration and duration of action in the central nervous system. This dual reuptake inhibition is believed to underlie its antidepressant effect. Desvenlafaxine has minimal affinity for dopaminergic, muscarinic, histaminergic, or alpha-adrenergic receptors, which distinguishes it from older tricyclic antidepressants and contributes to a more favorable side-effect profile.

C (legacy FDA pregnancy category, prior to the current labeling system)

Nevola is not approved for use in pediatric patients. Safety and efficacy of Nevola have not been established in children and adolescents younger than 18 years. Additionally, Nevola carries a boxed warning regarding increased risk of suicidal thoughts and behavior in children, adolescents, and young adults up to age 24, so its use in this age group should only be considered by a specialist physician after careful evaluation of risks and benefits, with close monitoring.